Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an update.
Ondine Biomedical Inc. has commenced patient recruitment for a pilot study at Royal Columbian Hospital to evaluate its Steriwave nasal photodisinfection technology in intensive care units (ICUs). This study aims to assess the feasibility of a larger trial to reduce hospital-acquired infections among critically ill patients, potentially expanding the market for Steriwave. The study’s outcome could significantly impact ICU infection control practices, offering a non-antibiotic alternative to combat antimicrobial resistance. Additionally, Ondine will issue new shares as part of a milestone payment agreement related to the study.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, including the Steriwave nasal photodisinfection system, which is approved in Canada and several other countries and is undergoing clinical trials in the US.
YTD Price Performance: 17.14%
Average Trading Volume: 272,005
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £41.41M
See more insights into OBI stock on TipRanks’ Stock Analysis page.